277 related articles for article (PubMed ID: 11485406)
1. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
Wilson JA; Bray M; Bakken R; Hart MK
Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
[TBL] [Abstract][Full Text] [Related]
2. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
3. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
Hevey M; Negley D; Pushko P; Smith J; Schmaljohn A
Virology; 1998 Nov; 251(1):28-37. PubMed ID: 9813200
[TBL] [Abstract][Full Text] [Related]
4. Evaluation in nonhuman primates of vaccines against Ebola virus.
Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB
Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S
Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650
[TBL] [Abstract][Full Text] [Related]
6. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
Vanderzanden L; Bray M; Fuller D; Roberts T; Custer D; Spik K; Jahrling P; Huggins J; Schmaljohn A; Schmaljohn C
Virology; 1998 Jun; 246(1):134-44. PubMed ID: 9657001
[TBL] [Abstract][Full Text] [Related]
8. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
9. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
[TBL] [Abstract][Full Text] [Related]
10. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
[TBL] [Abstract][Full Text] [Related]
11. Analysis of CD8
Sakabe S; Sullivan BM; Hartnett JN; Robles-Sikisaka R; Gangavarapu K; Cubitt B; Ware BC; Kotliar D; Branco LM; Goba A; Momoh M; Sandi JD; Kanneh L; Grant DS; Garry RF; Andersen KG; de la Torre JC; Sabeti PC; Schieffelin JS; Oldstone MBA
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):E7578-E7586. PubMed ID: 30038008
[TBL] [Abstract][Full Text] [Related]
12. Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes.
Sundar K; Boesen A; Coico R
Virology; 2007 Apr; 360(2):257-63. PubMed ID: 17123567
[TBL] [Abstract][Full Text] [Related]
13. Development of a preventive vaccine for Ebola virus infection in primates.
Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
[TBL] [Abstract][Full Text] [Related]
14. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
[TBL] [Abstract][Full Text] [Related]
15. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
16. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
Jones SM; Feldmann H; Ströher U; Geisbert JB; Fernando L; Grolla A; Klenk HD; Sullivan NJ; Volchkov VE; Fritz EA; Daddario KM; Hensley LE; Jahrling PB; Geisbert TW
Nat Med; 2005 Jul; 11(7):786-90. PubMed ID: 15937495
[TBL] [Abstract][Full Text] [Related]
17. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
19. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.
Wilson JA; Hart MK
J Virol; 2001 Mar; 75(6):2660-4. PubMed ID: 11222689
[TBL] [Abstract][Full Text] [Related]
20. Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.
Lehrer AT; Wong TS; Lieberman MM; Humphreys T; Clements DE; Bakken RR; Hart MK; Pratt WD; Dye JM
Vaccine; 2018 May; 36(22):3090-3100. PubMed ID: 28216187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
